Questcor (NASDAQ: QCOR) is one of the most shorted health-care stocks on the market. Despite the company's profitability and strong cash flow, shares have taken a big hit as concerns arose regarding its top selling drug, Acthar. In this video, Motley Fool health-care analyst David Williamson reviews the bear case against Questcor and whether they are likely right in their assumptions.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Questcor is the second most shorted company in the entire health-care sector.
Brenton Flynn, David Williamson, and The Motley Fool have no positions in the stocks mentioned above. Follow David on Twitter @MotleyDavid.
Motley Fool newsletter services recommend UnitedHealth Group. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Aetna Inc.
AET
UnitedHealth Group
UNH
$302.08
(-1.67%)
$-5.12
Biogen
BIIB
$127.01
(0.37%)
$0.47
Humana
HUM
$239.69
(-1.52%)
$-3.71
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Should You Forget Medical Properties Trust and Buy These Unstoppable Dividend Stocks Instead?
Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week
Is Oscar Health Stock Still a Buy?
Prediction: Wall Street's Latest Stock-Split Stock -- Up 60,120% Year-to-Date -- Is Going to Implode... It's Just a Matter of Time
1 Undervalued Growth Stock That Could Go Parabolic Soon
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.